Security record · archived quarter
CLDX
Celldex Therapeutics, Inc. · Healthcare · Biotechnology
11Tracked holders
—Δ holders
17.48MShares held
$646.94MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 87 | +8 | 50.70M | $1.89B | +11 | −3 |
| Q1 2026 | 82 | +10 | 42.54M | $1.35B | +12 | −2 |
| Q4 2025 | 72 | 0 | 42.78M | $1.16B | — | — |
| Q3 2025 | 17 | 0 | 35.45M | $917.00M | — | — |
| Q2 2025 | 14 | 0 | 33.46M | $680.97M | — | — |
| Q1 2025 | 11 | -1 | 21.24M | $385.48M | — | −1 |
| Q4 2024 | 12 | +1 | 21.78M | $550.46M | +2 | −1 |
| Q3 2024 | 10 | -1 | 17.69M | $601.30M | — | −1 |
| Q2 2024 | 11 | — | 17.48M | $646.94M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 8.08M | — | $298.89M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 8.08M | — | $298.89M | 0.1% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 8.08M | — | $298.89M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 8.08M | — | $298.89M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 8.08M | — | $298.89M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 8.08M | — | $298.89M | 0.1% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 8.08M | — | $298.89M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 8.08M | — | $298.89M | 0.1% | n/c | 1 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 3.17M | — | $117.41M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 3.17M | — | $117.41M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Point72 Asset Management ✦ | 1.94M | — | $71.73M | 0.2% | n/c | 1 | SEC ↗ |
| 12 | Geode Capital Management ✦ (passive) | 1.53M | — | $56.78M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Geode Capital Management ✦ (passive) | 1.53M | — | $56.78M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Marshall Wace ✦ | 1.38M | — | $50.99M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 845.56K | — | $31.29M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 845.56K | — | $31.29M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 321.21K | — | $11.89M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 321.21K | — | $11.89M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Fisher Asset Management ✦ | 120.54K | — | $4.46M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Millennium Management ✦ | 43.75K | — | $1.62M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Renaissance Technologies ✦ | 42.79K | — | $1.58M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 7.86K | — | $290,788 | 0.0% | n/c | 1 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 7.86K | — | $290,788 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 227 holders, 72.32M shares, $2.21B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API